In this morning’s Stock report under the Health & Biotech Sector...

In this morning’s Stock report under the Health & Biotech Sector they mentioned ASX stocks leading clinical trials in Australia…..
Among the list was LTP


Here is a copy and paste……..not much we don’t already know but it was nice to get a mention in dispatches

“LTP recently completed a pivotal bioequivalence clinical study in Sydney of its lead asset Spontan nasal spray treatment for erectile dysfunction (ED). Initial results of the study showed Spontan was able to achieve rapid absorption and faster onset of action than traditional oral PDE5 inhibitors, encompassing household names like Viagra.LTP announced it had achieved a significant milestone in August with the first patients having begun using Spontan under the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme (APS).“Spontan is a truly innovative, fast-acting treatment, which is on track to disrupt the established blockbuster oral PDE5 market. Current oral tablets can take up to one hour to take effect, and many men are dissatisfied with the results as they don’t always work or in the time desired,” said chair Lee Rodne.“We were thrilled to welcome men in Australia to participate in our pivotal study recently – a crucial step in clinical validation and our expedited regulatory journey for Spontan, as we prepare to bring this product to the world.The speed of recruitment and preliminary results we shared recently, are truly encouraging.”